EP300 and cancer: Additionally, given that proteasome inhibitors and drugs that affect protein-triage decisions have enter clinical testing in cancer and neurdegeneration [15], [55], our data may foster the development of novel molecules that, by targeting different p300 domains, affect life and death decisions in various pathogenic conditions.